A Single- and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of LY4355756 in Healthy Participants
The purpose of the study is to assess how LY4355756 is absorbed by the body and how safe it is to healthy participants.
There will be four inpatient stays at the clinical research unit (CRU). For Part A there will be 5 continuous days, Part B 22 continuous days, Part C 5 continuous days in each of the 3 periods, and Part D 18 continuous days in the CRU.
Eli Lilly and Company